Desmopressin is one of the most widely and successfully used pharmacotherapies for the management of primary monosymptomatic enuresis (ME). At the 24th Congress of the European Society of Paediatric Urology in Genoa, Italy, Dr. Berk Burgu from Ankara University, Turkey, discussed the findings of a prospective, randomized, multicenter, placebo-controlled trial in which the effect of desmopressin withdrawal was examined in 106 ME patients. He described the withdrawal program utilized in his study, highlighted the key findings, and discussed the research group’s future planned studies.